Skip to main content
Top
Published in: Current Treatment Options in Psychiatry 2/2015

01-06-2015 | Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Current Treatments for Delusional Disorder

Authors: Mohsen Jalali Roudsari, MD, Jinsoo Chun, Ph.D., Theo C. Manschreck, MD, MPH

Published in: Current Treatment Options in Psychiatry | Issue 2/2015

Login to get access

Opinion Statement

Delusional disorders form part of the spectrum of psychotic disorders in psychiatry. They are poorly understood in practically every aspect of their nature, including cause, phenomenology, prevalence, comorbidity, course, treatment, and prognosis. The key symptom in delusional disorders is one or more delusions. A cardinal characteristic of delusional disorder, conviction that one is not mentally ill, contributes complexity to the treatment challenges and profoundly affects the therapeutic relationship. Diagnosis and differential diagnosis are critical tasks. Delusional conditions may arise from many sources and, only when the case conforms to the criteria and is clearly idiopathic—is a primary delusional disorder—can we feel confident that the patient suffers from delusional disorder rather than a secondary delusional condition. Adequate treatment follows principles for the treatment of delusions. First line pharmacological treatment for delusional disorder is antipsychotic medication, both first and second-generation agents, and some evidence suggests that clozapine may be effective in certain cases. The assumption in such a formulation is that the delusion(s) encountered in delusional disorders respond as a class of symptoms found in different disorders. Hence, the approach for failed interventions with these agents may be similar to that proposed for the treatment of schizophrenia or other psychotic disorders. Namely, searching for evidence of failure to take medication, inadequate dosing, a missed diagnosis of a substance disorder, medical condition, or even another psychiatric disorder should be considered. For individuals with delusional disorders who are also experiencing comorbid depression or anxiety, the addition of appropriate agents for those symptoms may provide a synergistic strategy for overall effectiveness. Psychotherapy is another important clinical tool. Cognitive behavioral therapy focusing on different aspects of delusions (i.e., anxiety, reasoning biases, faulty logic, etc.) has demonstrated some value for at least short-term improvement. Various techniques may be useful in allying with the patient and supplying means to assist in managing their thinking and approach to circumstances and factors that promote delusion formation and encourage actions taken to respond. A significant problem in applying what we know about delusional disorders to treatment is the limited available evidence. Lack of randomized controlled trials, which form the standard in most clinical disorders, is a major shortcoming. Recent observations of compromised cognitive functioning in working memory, attention, and executive function should be replicated with similar standards. Systematic case studies and large series are useful, and a growing effort to be more rigorous methodologically in all contributions including case registries and longer follow-up studies is promising. Nevertheless, our knowledge remains less than optimal. These comments apply not only to pharmacological observations but also to those of neuropsychological and psychotherapeutic studies.
Literature
1.
go back to reference Association AP. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC. 2013. Association AP. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC. 2013.
2.••
go back to reference Gonzalez-Rodriguez A, Molina-Andreu O, Imaz Gurrutxaga ML, Catalan Campos R, Bernardo Arroyo M. A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. Rev Psiquiatr Salud Ment. 2014;7(2):64–71. doi:10.1016/j.rpsm.2013.01.004. A longitudinal retrospective study with one-year follow-up, to describe demographic and clinical features in DD as well as to compare attendance at psychiatry follow-up visit in 3 treatment groups: LAIs, oral risperidone, or other oral SGAs. N = 78. At one year, higher treatment maintenance rates and less antidepressant and benzodiazepine usage were found in LAIs group compared to oral SGAs. Gonzalez-Rodriguez A, Molina-Andreu O, Imaz Gurrutxaga ML, Catalan Campos R, Bernardo Arroyo M. A descriptive retrospective study of the treatment and outpatient service use in a clinical group of delusional disorder patients. Rev Psiquiatr Salud Ment. 2014;7(2):64–71. doi:10.​1016/​j.​rpsm.​2013.​01.​004. A longitudinal retrospective study with one-year follow-up, to describe demographic and clinical features in DD as well as to compare attendance at psychiatry follow-up visit in 3 treatment groups: LAIs, oral risperidone, or other oral SGAs. N = 78. At one year, higher treatment maintenance rates and less antidepressant and benzodiazepine usage were found in LAIs group compared to oral SGAs.
3.••
go back to reference Gonzalez-Rodriguez A, Molina-Andreu O, Penades R, Bernardo M, Catalan R. Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. Int Clin Psychopharmacol. 2014;29(3):177–80. doi:10.1097/yic.0000000000000020. A longitudinal observational study on delusional disorder with 6-month follow-up—N = 45—to describe demographic and clinical features in DD as well as to compare treatment outcomes between two forms of atypical antipsychotics (oral antipsychotics vs injectable paliperidone or risperidone) in two clinical subgroups of DD patients (without hallucinations vs with non-prominent hallucinations). This study is among a few studies on DD which use objective measures such as PANSS, Hamilton Rating Scale for Depression, the Personal and Social Performance Scale and drug compliance assessment to assess the outcomes. The LAIs group showed a trend toward lower scores in PANSS positive symptoms compared to the oral antipsychotics groups, and significantly lower scores in PANSS negative symptoms.CrossRefPubMed Gonzalez-Rodriguez A, Molina-Andreu O, Penades R, Bernardo M, Catalan R. Effectiveness of long-acting injectable antipsychotics in delusional disorders with nonprominent hallucinations and without hallucinations. Int Clin Psychopharmacol. 2014;29(3):177–80. doi:10.​1097/​yic.​0000000000000020​. A longitudinal observational study on delusional disorder with 6-month follow-up—N = 45—to describe demographic and clinical features in DD as well as to compare treatment outcomes between two forms of atypical antipsychotics (oral antipsychotics vs injectable paliperidone or risperidone) in two clinical subgroups of DD patients (without hallucinations vs with non-prominent hallucinations). This study is among a few studies on DD which use objective measures such as PANSS, Hamilton Rating Scale for Depression, the Personal and Social Performance Scale and drug compliance assessment to assess the outcomes. The LAIs group showed a trend toward lower scores in PANSS positive symptoms compared to the oral antipsychotics groups, and significantly lower scores in PANSS negative symptoms.CrossRefPubMed
7.••
go back to reference Bhatia MS, Jhanjee A, Srivastava S. Delusional infestation: a clinical profile. Asian J Psychiatr. 2013;6(2):124–7. doi:10.1016/j.ajp.2012.09.008. Is a case series of 50 cases with delusion of parasitosis and described the demographic and clinical features as well as pharmacological treatment outcomes. 45 patients received SGAs. Antipsychotic treatment was associated with a high positive response rate—full or partial remission, with risperidone as the most frequent medication followed by olanzapine. 10% of DOP patients had comorbid depression and fully remitted with fluoxetine monotherapy.CrossRefPubMed Bhatia MS, Jhanjee A, Srivastava S. Delusional infestation: a clinical profile. Asian J Psychiatr. 2013;6(2):124–7. doi:10.​1016/​j.​ajp.​2012.​09.​008. Is a case series of 50 cases with delusion of parasitosis and described the demographic and clinical features as well as pharmacological treatment outcomes. 45 patients received SGAs. Antipsychotic treatment was associated with a high positive response rate—full or partial remission, with risperidone as the most frequent medication followed by olanzapine. 10% of DOP patients had comorbid depression and fully remitted with fluoxetine monotherapy.CrossRefPubMed
8.••
go back to reference Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry. 1995;40(10):616–22. A review of 209 reports of cases with DD published between 1961 and 1994, describing the demographic and clinical features as well as pharmacological treatment outcomes. All the patients received neuroleptics. If treated adequately, DD is a disorder with good prognosis. More than 80% of patients showed partial or complete remission. Pimozide was suggested as the first line treatment.PubMed Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry. 1995;40(10):616–22. A review of 209 reports of cases with DD published between 1961 and 1994, describing the demographic and clinical features as well as pharmacological treatment outcomes. All the patients received neuroleptics. If treated adequately, DD is a disorder with good prognosis. More than 80% of patients showed partial or complete remission. Pimozide was suggested as the first line treatment.PubMed
9.••
go back to reference Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry. 2006;51(2):114–9. A review of 134 cases with DD published between 1995 and 2004, described the demographic and clinical features as well as pharmacological treatment outcomes. Antipsychotic therapy was associated with high rate of positive results—full or partial remission. There was no significant difference between FGAs and SGAs in outcomes. Pimozide was associated with greater rate of improvement in somatic delusion compared to other types of delusions.PubMed Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry. 2006;51(2):114–9. A review of 134 cases with DD published between 1995 and 2004, described the demographic and clinical features as well as pharmacological treatment outcomes. Antipsychotic therapy was associated with high rate of positive results—full or partial remission. There was no significant difference between FGAs and SGAs in outcomes. Pimozide was associated with greater rate of improvement in somatic delusion compared to other types of delusions.PubMed
11.••
go back to reference de Portugal E, Martinez C, Gonzalez N, del Amo V, Haro JM, Cervilla JA. Clinical and cognitive correlates of psychiatric comorbidity in delusional disorder outpatients. Aust N Z J Psychiatry. 2011;45(5):416–25. doi:10.3109/00048674.2010.551279. Used objective measured to investigate the prevalence, and the possible correlation between psychiatric comorbidities and clinical and cognitive features in DD (n = 86). Depression and anxiety were the most common comorbidities. Those with psychiatric comorbidity showed greater emotion-related psychopathology and those without psychiatric comorbidity were associated with more cognitive disturbances.CrossRefPubMed de Portugal E, Martinez C, Gonzalez N, del Amo V, Haro JM, Cervilla JA. Clinical and cognitive correlates of psychiatric comorbidity in delusional disorder outpatients. Aust N Z J Psychiatry. 2011;45(5):416–25. doi:10.​3109/​00048674.​2010.​551279. Used objective measured to investigate the prevalence, and the possible correlation between psychiatric comorbidities and clinical and cognitive features in DD (n = 86). Depression and anxiety were the most common comorbidities. Those with psychiatric comorbidity showed greater emotion-related psychopathology and those without psychiatric comorbidity were associated with more cognitive disturbances.CrossRefPubMed
12.••
go back to reference Wustmann T, Pillmann F, Marneros A. Gender-related features of persistent delusional disorders. Eur Arch Psychiatry Clin Neurosci. 2011;261(1):29–36. doi:10.1007/s00406-010-0130-1. As part of the Halle Delusional Syndrome Study (HADES-Study), described gender-related features of DD in 43 inpatients DD. There was no gender difference in the prevalence rate of DD. Women became ill significantly later than men. They also showed a higher diagnosis stability than men, while men tended more frequently to be re-diagnosed with schizophrenia and schizoaffective disorder.CrossRefPubMed Wustmann T, Pillmann F, Marneros A. Gender-related features of persistent delusional disorders. Eur Arch Psychiatry Clin Neurosci. 2011;261(1):29–36. doi:10.​1007/​s00406-010-0130-1. As part of the Halle Delusional Syndrome Study (HADES-Study), described gender-related features of DD in 43 inpatients DD. There was no gender difference in the prevalence rate of DD. Women became ill significantly later than men. They also showed a higher diagnosis stability than men, while men tended more frequently to be re-diagnosed with schizophrenia and schizoaffective disorder.CrossRefPubMed
15.
21.
go back to reference De Berardis D, Serroni N, Marini S, Rapini G, Valchera A, Fornaro M, et al. Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup. Case Rep Psychiatry. 2013;2013:913248. doi:10.1155/2013/913248.PubMedCentralPubMed De Berardis D, Serroni N, Marini S, Rapini G, Valchera A, Fornaro M, et al. Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup. Case Rep Psychiatry. 2013;2013:913248. doi:10.​1155/​2013/​913248.PubMedCentralPubMed
25.
go back to reference Contreras-Ferrer P, de Paz NM, Cejas-Mendez MR, Rodriguez-Martin M, Souto R, Bustinduy MG. Ziprasidone in the treatment of delusional parasitosis. Case Rep Dermatol. 2012;4(2):150–3.CrossRefPubMedCentralPubMed Contreras-Ferrer P, de Paz NM, Cejas-Mendez MR, Rodriguez-Martin M, Souto R, Bustinduy MG. Ziprasidone in the treatment of delusional parasitosis. Case Rep Dermatol. 2012;4(2):150–3.CrossRefPubMedCentralPubMed
27.
go back to reference Altunay IK, Ates B, Mercan S, Demirci GT, Kayaoglu S. Variable clinical presentations of secondary delusional infestation: an experience of six cases from a psychodermatology clinic. Int J Psychiatry Med. 2012;44(4):335–50.CrossRefPubMed Altunay IK, Ates B, Mercan S, Demirci GT, Kayaoglu S. Variable clinical presentations of secondary delusional infestation: an experience of six cases from a psychodermatology clinic. Int J Psychiatry Med. 2012;44(4):335–50.CrossRefPubMed
28.
go back to reference Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate Jr CA, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70(4):458–66.CrossRefPubMedCentralPubMed Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate Jr CA, et al. McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70(4):458–66.CrossRefPubMedCentralPubMed
29.
go back to reference Perugi G, Poletti M, Logi C, Berti C, Romano A, Del Dotto P, et al. Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia. Neurol Sci. 2013;34(9):1537–41. doi:10.1007/s10072-012-1276-6.CrossRefPubMed Perugi G, Poletti M, Logi C, Berti C, Romano A, Del Dotto P, et al. Diagnosis, assessment and management of delusional jealousy in Parkinson’s disease with and without dementia. Neurol Sci. 2013;34(9):1537–41. doi:10.​1007/​s10072-012-1276-6.CrossRefPubMed
31.
go back to reference Herbel BL, Stelmach H. Involuntary medication treatment for competency restoration of 22 defendants with delusional disorder. J Am Acad Psychiatry Law. 2007;35(1):47–59.PubMed Herbel BL, Stelmach H. Involuntary medication treatment for competency restoration of 22 defendants with delusional disorder. J Am Acad Psychiatry Law. 2007;35(1):47–59.PubMed
32.
go back to reference McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–60. doi:10.1176/ajp.2007.164.7.1050.CrossRefPubMed McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–60. doi:10.​1176/​ajp.​2007.​164.​7.​1050.CrossRefPubMed
34.
go back to reference Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163(12):2096–102. doi:10.1176/appi.ajp.163.12.2096.CrossRefPubMed Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163(12):2096–102. doi:10.​1176/​appi.​ajp.​163.​12.​2096.CrossRefPubMed
35.
go back to reference Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Brit J Psychiatry: J Mental Sci. 2005;187:537–43. doi:10.1192/bjp.187.6.537.CrossRef Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Brit J Psychiatry: J Mental Sci. 2005;187:537–43. doi:10.​1192/​bjp.​187.​6.​537.CrossRef
37.
go back to reference Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274–80. doi:10.1097/JCP.0b013e3182199bcc.CrossRefPubMed Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274–80. doi:10.​1097/​JCP.​0b013e3182199bcc​.CrossRefPubMed
38.
go back to reference Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol (Oxford, England). 2011;25(5):646–66. doi:10.1177/0269881110376685. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol (Oxford, England). 2011;25(5):646–66. doi:10.​1177/​0269881110376685​.
39.
41.••
go back to reference González-Rodríguez A, Molina-Andreu O, Odriozola VN, Ferrer CG, Penadés R, Catalán R. Delusional disorder: an overview of affective symptoms and antidepressant use. Eur J Psychiat. 2013;27(4):265–76. doi:10.4321/S0213-61632013000400005. Is a review of literature to describe the frequency of affective symptoms and antidepressant use in DD (34 related articles published between 1980 to 2012). Authors reported a high frequency of depressive symptoms in DD, but a low antidepressant usage rate. They noted relatively high antidepressant efficacy either as monotherapy or in combination with antipsychotics. They suggested that antidepressant may be useful in treatment of DD with or without comorbid depression. The most recent neuroimaging study with patients with delusional disorder (DD) with matched controls investigating working memory.CrossRef González-Rodríguez A, Molina-Andreu O, Odriozola VN, Ferrer CG, Penadés R, Catalán R. Delusional disorder: an overview of affective symptoms and antidepressant use. Eur J Psychiat. 2013;27(4):265–76. doi:10.​4321/​S0213-6163201300040000​5. Is a review of literature to describe the frequency of affective symptoms and antidepressant use in DD (34 related articles published between 1980 to 2012). Authors reported a high frequency of depressive symptoms in DD, but a low antidepressant usage rate. They noted relatively high antidepressant efficacy either as monotherapy or in combination with antipsychotics. They suggested that antidepressant may be useful in treatment of DD with or without comorbid depression. The most recent neuroimaging study with patients with delusional disorder (DD) with matched controls investigating working memory.CrossRef
44.••
go back to reference Oflaz S, Akyuz F, Hamamci A, Firat Z, Keskinkilic C, Kilickesmez O, et al. Working memory dysfunction in delusional disorders: an fMRI investigation. J Psychiatr Res. 2014;56:43–9. doi:10.1016/j.jpsychires.2014.04.022. The most recent neuroimaging study with patients with delusional disorder (DD) with matched controls investigating working memory.CrossRefPubMed Oflaz S, Akyuz F, Hamamci A, Firat Z, Keskinkilic C, Kilickesmez O, et al. Working memory dysfunction in delusional disorders: an fMRI investigation. J Psychiatr Res. 2014;56:43–9. doi:10.​1016/​j.​jpsychires.​2014.​04.​022. The most recent neuroimaging study with patients with delusional disorder (DD) with matched controls investigating working memory.CrossRefPubMed
45.••
go back to reference Freeman D, Garety P. Advances in understanding and treating persecutory delusions: a review. Soc Psychiatry Psychiatr Epidemiol. 2014;49(8):1179–89. doi:10.1007/s00127-014-0928-7. Introduced the six main proximal causal factors for delusions: worry thinking style, negative beliefs about the self, interpersonal sensitivity, sleep disturbances, anomalous internal experience, and reasoning biases.CrossRefPubMedCentralPubMed Freeman D, Garety P. Advances in understanding and treating persecutory delusions: a review. Soc Psychiatry Psychiatr Epidemiol. 2014;49(8):1179–89. doi:10.​1007/​s00127-014-0928-7. Introduced the six main proximal causal factors for delusions: worry thinking style, negative beliefs about the self, interpersonal sensitivity, sleep disturbances, anomalous internal experience, and reasoning biases.CrossRefPubMedCentralPubMed
46.••
go back to reference Garety P, Joyce E, Jolley S, Emsley R, Waller H, Kuipers E, et al. Neuropsychological functioning and jumping to conclusions in delusions. Schizophr Res. 2013;150(2-3):570–4. doi:10.1016/j.schres.2013.08.035. Introduced the contributing cognitive factors to the occurrence of reasoning bias, specifically jumping to conclusion (JTC) among patients with delusions.CrossRefPubMedCentralPubMed Garety P, Joyce E, Jolley S, Emsley R, Waller H, Kuipers E, et al. Neuropsychological functioning and jumping to conclusions in delusions. Schizophr Res. 2013;150(2-3):570–4. doi:10.​1016/​j.​schres.​2013.​08.​035. Introduced the contributing cognitive factors to the occurrence of reasoning bias, specifically jumping to conclusion (JTC) among patients with delusions.CrossRefPubMedCentralPubMed
47.••
go back to reference Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, et al. How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull. 2015;41(2):391–9. doi:10.1093/schbul/sbu098. A randomized, placebo-controlled study demonstrated that anomalous experiences and paranoia can be induced by intravenous administration of THC.CrossRefPubMedCentralPubMed Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, et al. How cannabis causes paranoia: using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull. 2015;41(2):391–9. doi:10.​1093/​schbul/​sbu098. A randomized, placebo-controlled study demonstrated that anomalous experiences and paranoia can be induced by intravenous administration of THC.CrossRefPubMedCentralPubMed
Metadata
Title
Current Treatments for Delusional Disorder
Authors
Mohsen Jalali Roudsari, MD
Jinsoo Chun, Ph.D.
Theo C. Manschreck, MD, MPH
Publication date
01-06-2015
Publisher
Springer International Publishing
Published in
Current Treatment Options in Psychiatry / Issue 2/2015
Electronic ISSN: 2196-3061
DOI
https://doi.org/10.1007/s40501-015-0044-7

Other articles of this Issue 2/2015

Current Treatment Options in Psychiatry 2/2015 Go to the issue

Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Treatment Strategies for Cannabis Use in Schizophrenia

Substance Use Disorders (FG Moeller, Section Editor)

Outcome Measures in Medication Trials for Substance Use Disorders

Post-Traumatic Stress Disorders (T Garacioti and K Chard, Section Editors)

Prazosin for the Treatment of PTSD

Substance Use Disorders (FG Moeller, Section Editor)

Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Preventing Violence in Patients with Schizophrenia